Kinetics

Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024

Retrieved on: 
Mercoledì, Giugno 5, 2024
Cell, Bemnifosbuvir, Congress, Tissue, Absorption, Patient, Sofosbuvir, NS5B, Doctor of Philosophy, Infection, OATP1B3, Drug interaction, Șaeș, ADME, EASL, CYP450, Cirrhosis, HCV, Risk, Safety, Brain, DAA, Genotype, University, RAS, OATP1B1, Rass, Kinetics, MD, Viral, Pharmacokinetics, Metabolism, Rat, NS5A, DDI, Pharmaceutical industry

BOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced new data from the lead-in cohort (n=60) of the Company’s ongoing Phase 2 combination study of bemnifosbuvir, an oral nucleotide NS5B polymerase inhibitor, and ruzasvir, an oral NS5A inhibitor, for the treatment of hepatitis C virus (HCV). With an 8-week treatment duration, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12), which is the primary efficacy endpoint of the study.

Key Points: 
  • These data are being presented at the European Association for the Study of the Liver (EASL) Congress taking place June 5-8, 2024, in Milan, Italy.
  • Patient demographics have changed, and the pace of new HCV infections is quickly outpacing the rate of those being treated.
  • “The data being presented at EASL demonstrate a potential best-in-class profile that combines the most compelling attributes of current HCV drug treatments through the innovative combination of bemnifosbuvir and ruzasvir.
  • “I am excited about the initial bemnifosbuvir and ruzasvir combination data.

Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Retrieved on: 
Venerdì, Maggio 31, 2024
NGS, ADPT, Patient, Progression-free survival, Bone marrow, Chronic lymphocytic leukemia, University, Clinical trial, PFS, Drug development, Safety, CLL, MRD, Blood, EHA, ALL, Multiple myeloma, ASCO, Acute lymphoblastic leukemia, Genetics, Kinetics, Society, European Hematology Association, Annual general meeting

The clinical trial data and real-world evidence to be presented at ASCO and EHA further underscore the clinical benefit of specific and sensitive MRD assessment with clonoSEQ.

Key Points: 
  • The clinical trial data and real-world evidence to be presented at ASCO and EHA further underscore the clinical benefit of specific and sensitive MRD assessment with clonoSEQ.
  • These data support the potential for a less invasive method to monitor MRD and track a patient’s response to therapy in ALL.
  • In patients with chronic lymphocytic leukemia (CLL), data from clinical trials highlighted the use of clonoSEQ to support individualized MRD-guided treatment modification.
  • clonoSEQ-related data to be presented at both ASCO and EHA:

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

Retrieved on: 
Giovedì, Maggio 23, 2024
Clinical research, Patient, Pharmacokinetics, Juan Carlos Ferrero, Interleukin, VISTA, FDA, Sensei, Endometrial cancer, Safety, PD-1, Cancer, TMDD, ASCO, CRC, Kinetics, Poster, Society, Aes, Therapy, Immunotherapy, Webcast, NEXT, Antibody, MSS, CRS, Tumor necrosis factor, Pharmaceutical industry

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation).

Key Points: 
  • There is a continued unmet need for patient populations that have become resistant or don’t respond to current immunotherapy treatment options.
  • I look forward to continuing to evaluate its progress.”
    The dose escalation portion of the Phase 1/2 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101.
  • These clinical data are consistent with preclinical studies suggesting therapeutically relevant clinical doses of SNS-101 at 3mg/kg or higher.
  • Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101, and lead author of the SNS-101 poster.

Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer

Retrieved on: 
Martedì, Maggio 21, 2024
ASX, PET, Hook effect, Isotope, Patient, Pharmacokinetics, Liver, Data, PSMA, Safety, Bone marrow, TAT, TLX, Blood, Prostate cancer, Positron emission tomography, System, Kinetics, Actinium-225, Vaccine

CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.

Key Points: 
  • CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer.
  • Successful completion of mass dose escalation study establishes a baseline dosing schedule for future studies of TLX592 using actinium-225.
  • MELBOURNE, Australia, May 21, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of CUPID1, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate cancer.
  • TLX592 (225Ac-PSMA-RADmAb®) is Telix’s investigational “next generation” targeted alpha therapy (TAT) for the treatment of prostate cancer and is the first clinical program to utilise Telix’s proprietary RADmAb® engineered antibody technology.

Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Martedì, Maggio 14, 2024
Plasma, SOC, Risk, FDA, Ageing, Electrocardiography, Week, Fast Track, HCV, Kinetics, RNA, Research, QRS, Standard of care, QT, Bemnifosbuvir, Patient, QT interval, Infection, Cardiotoxicity, SVR4, Security (finance), Second generation, Administration, COVID-19, Food, Clinical trial, Viral, Safety, Hospital, Viral load, SVR, Doctor of Philosophy, NS5A, EASL, BID, Heart rate, Tax, NS5B, Immunodeficiency, Death, Cirrhosis, PR, Development, Pharmaceutical industry

BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

Key Points: 
  • BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
  • Final results from the 60-patient lead-in cohort confirmed a 98% SVR4 rate across all genotypes from 58 of 59 patients.
  • Topline results from all patients enrolled in the Phase 2 study are anticipated in the second half of 2024.
  • In April 2024, Atea presented Phase 1 data showing that bemnifosbuvir does not alter cardiac repolarization.

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

Retrieved on: 
Mercoledì, Maggio 22, 2024
Biotechnology, Health, Genetics, Health Technology, Oncology, Genomics, Patient, Prevalence, DNA, NeXT, Colorectal cancer, Circulating tumor DNA, Ultra, Breast cancer, Neoplasm, MRD, ASCO, CRC, THP, Kinetics, Society, Daphne, Annual general meeting, PSNL, Medical imaging

“As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.

Key Points: 
  • “As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO 2024’s Clinical Science Symposium”, said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
  • The two studies that were selected to appear as podium presentations are:
    Overview: Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
  • Details of the Personalis abstracts are outlined below, and further details about the poster presentations can be found here .
  • Overview: Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

Independent Studies Further Validate the American Rare Earths’ (ARR) Halleck Creek Project

Retrieved on: 
Lunedì, Maggio 6, 2024
Tetra, EERE, Society, Rare-earth element, Uranium, ARR, Allanite, Kinetics, Energy efficiency, ASX, Mineral, Renewable energy, Research, Primary energy, Concentrate, Silica gel, Tetra Tech, Optimism, Competent person, Virginia Tech, Temperature, Wood, Acid, Liu, REE, Thorium, Engineering

DENVER, May 06, 2024 (GLOBE NEWSWIRE) -- American Rare Earths (ASX: ARR | OTCQX: ARRNF and AMRRY) (“ARR” or the “Company”) is pleased to announce results from a metallurgical study on leaching extraction of REE from Halleck Creek ore by low temperature, direct acid leaching. The U.S. Department of Energy’s Office of Energy Efficiency and Renewable Energy (“EERE”) awarded a three-year (2022-2025) research contract to Phinix, LLC with American Rare Earth and Virginia Tech as team members. This metallurgical study was carried out by researchers at the Department of Mining and Minerals Engineering at Virginia Tech. These positive results further confirm the findings of the metallurgical testwork carried out by Wood PLC1 which were previously announced by ARR.

Key Points: 
  • Fast leaching kinetics are attributable to Halleck Creek metamict allanite structure, with 65% of REEs extracted in the first 10 minutes of leaching.
  • Halleck Creek ore is less refractory than monazite or bastnaesite, which cannot be leached using low-temperature acid tank leaching.
  • Green and Smart Mining Engineering - (Xiao and Zhang, 2024)
    High-grade rare-earth enriched Halleck Creek ore highlights its economic potential.
  • Donald Swartz, Chief Executive Officer of American Rare Earths commented:
    “We’re extremely pleased with the leaching results which further validate the recent scoping study assumptions and our optimism around the project.

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

Retrieved on: 
Giovedì, Maggio 2, 2024
TARC, Kinetics, Research, Patient, Dupilumab, ASLN, Biology, Biomarker, Atopic dermatitis, SAN, Pharmaceutical industry

The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.

Key Points: 
  • The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab.
  • The first part of the collaboration will focus on receptor biology and kinetics to investigate the cellular and molecular basis of eblasakimab’s potential for differentiation.
  • Under the new research collaboration, ASLAN and Zenyaku will conduct collaborative studies that will explore the biology of the IL-13 and IL-4 receptors, including the effects of biologics eblasakimab, dupilumab and lebrikizumab on each receptor subunit.
  • The results from this research collaboration will provide further insight into the differentiated receptor biology of targeting IL-13R versus IL-4R.

Eldorado Gold Reports First Quarter 2024 Financial and Operational Results; Steady Start to 2024

Retrieved on: 
Giovedì, Aprile 25, 2024
AISC, Kinetics, Olympias, Competence, Depreciation, Progress, Eldorado Gold, Ventilation, Assessment, Public expenditure, Engineering, Gold, Tax, Steel, GM, Pond, Burns, Workforce, Palladium

VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation (“Eldorado”, "Eldorado Gold" or “the Company”) today reports the Company’s financial and operational results for the first quarter of 2024.

Key Points: 
  • VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation (“Eldorado”, "Eldorado Gold" or “the Company”) today reports the Company’s financial and operational results for the first quarter of 2024.
  • Production and cost outlook: The Company is maintaining its 2024 annual production guidance of 505,000 to 555,000 ounces of gold.
  • The increase was driven by increased gold production and gold sales and higher average realized gold price.
  • In addition to the Operational Readiness team, as at March 31, 2024, there were over 600 personnel on site which is expected to ramp up to 1,300 during 2024.